𝛼SK or Searchbullish
Island Pharmaceuticals Ltd - Galidesivier approved for use in Ebola epidemic
SUMMARY
- Island Pharmaceuticals Ltd (ASX:ILA) is an antiviral therapeutics company targeting infectious diseases.
- The company has announced that, in response to the current Bundibugyo Ebola epidemic in Africa, it has secured government and regulatory approvals for the compassionate use of its drug Galidesivir as a treatment for infected patients.
- While ILA is progressing Galidesivir for Marburg virus disease through Non-Human Primate (NHP) studies under the FDA’s Animal Rule pathway, this development enables ILA the unique opportunity to generate prospective human efficacy, safety and virological data on a number of deadly filoviruses (including various strains of Ebola and Marburg), potentially demonstrating Galidesivir’s appeal as a broad-spectrum antiviral and thus expanding the commercial opportunities available to ILA.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Island Pharmaceuticals Ltd - Galidesivier approved for use in Ebola epidemic08 Jul 2026
x